Taxotere Prostate Cancer New Indication Registration Trial in China
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and
prednisone in subjects with hormone-refractory metastatic prostate cancer.